戴纳基公司已提交申请，寻求基于肌营养不良蛋白作为替代终点，为其疗法获得加速批准。此项提交标志着公司在推进其治疗杜氏肌营养不良症候选药物方面迈出了关键一步。加速批准途径允许监管机构依据可能合理预测临床益处的替代终点来批准治疗严重疾病的药物，这可以显著缩短药物到达患者手中的时间。肌营养不良蛋白水平的恢复被广泛认为是杜氏肌营养不良症治疗中一个有潜力的替代标志物。
戴纳基公司已提交申请，寻求基于肌营养不良蛋白作为替代终点，为其疗法获得加速批准。此项提交标志着公司在推进其治疗杜氏肌营养不良症候选药物方面迈出了关键一步。加速批准途径允许监管机构依据可能合理预测临床益处的替代终点来批准治疗严重疾病的药物，这可以显著缩短药物到达患者手中的时间。肌营养不良蛋白水平的恢复被广泛认为是杜氏肌营养不良症治疗中一个有潜力的替代标志物。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.